Entera Bio Past Earnings Performance

Past criteria checks 0/6

Entera Bio's earnings have been declining at an average annual rate of -1.8%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 24.8% per year.

Key information

-1.8%

Earnings growth rate

24.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-24.8%
Return on equity-85.6%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

May 31
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Feb 15
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Oct 13
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Aug 11

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Jun 10
We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Jan 21
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05
Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Entera Bio EPS misses by $0.22

Nov 19

Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis

Nov 09

Revenue & Expenses Breakdown
Beta

How Entera Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ENTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-945
30 Sep 230-1065
30 Jun 230-1165
31 Mar 230-1175
31 Dec 220-1386
30 Sep 220-1477
30 Jun 220-1478
31 Mar 220-1477
31 Dec 211-1267
30 Sep 211-1255
30 Jun 211-1055
31 Mar 210-1156
31 Dec 200-1156
30 Sep 200-1157
30 Jun 200-1357
31 Mar 200-1157
31 Dec 190-1147
30 Sep 191-1047
30 Jun 191-1247
31 Mar 191-938
31 Dec 181-1039
30 Sep 180-1158
30 Jun 180-1076
31 Mar 180-1385
31 Dec 170-1193
30 Sep 170-862
30 Jun 170-643
31 Mar 170-433
31 Dec 160-133

Quality Earnings: ENTX is currently unprofitable.

Growing Profit Margin: ENTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ENTX is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.

Accelerating Growth: Unable to compare ENTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: ENTX has a negative Return on Equity (-85.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.